C. Aeschlimann

456 total citations
8 papers, 361 citations indexed

About

C. Aeschlimann is a scholar working on Pathology and Forensic Medicine, Molecular Biology and Organic Chemistry. According to data from OpenAlex, C. Aeschlimann has authored 8 papers receiving a total of 361 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Pathology and Forensic Medicine, 3 papers in Molecular Biology and 2 papers in Organic Chemistry. Recurrent topics in C. Aeschlimann's work include Chemotherapy-induced organ toxicity mitigation (4 papers), Cancer therapeutics and mechanisms (1 paper) and Acute Myeloid Leukemia Research (1 paper). C. Aeschlimann is often cited by papers focused on Chemotherapy-induced organ toxicity mitigation (4 papers), Cancer therapeutics and mechanisms (1 paper) and Acute Myeloid Leukemia Research (1 paper). C. Aeschlimann collaborates with scholars based in Switzerland, United States and Poland. C. Aeschlimann's co-authors include A Küpfer, T. Cerny, T. Cerny, J. Gál, G. Félix, H Schefer, John G. Gerber, Laurence A. Nafié, Teresa B. Freedman and N. M. Blaton and has published in prestigious journals such as The Lancet, Journal of Hepatology and Drug Metabolism and Disposition.

In The Last Decade

C. Aeschlimann

8 papers receiving 351 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C. Aeschlimann Switzerland 7 160 68 67 43 43 8 361
Hisamitsu Nakahashi Japan 15 50 0.3× 104 1.5× 64 1.0× 22 0.5× 44 1.0× 37 571
Helene Markkanen Finland 14 62 0.4× 82 1.2× 32 0.5× 21 0.5× 23 0.5× 21 759
Merel van Nuland Netherlands 12 43 0.3× 59 0.9× 123 1.8× 32 0.7× 17 0.4× 29 378
Joseph J. Sikora United States 13 123 0.8× 148 2.2× 45 0.7× 37 0.9× 92 2.1× 25 640
G. Gothóni Finland 14 44 0.3× 96 1.4× 28 0.4× 22 0.5× 62 1.4× 25 488
John Kemp United Kingdom 14 56 0.3× 109 1.6× 96 1.4× 11 0.3× 64 1.5× 23 652
Tsutomu Arai Japan 16 46 0.3× 145 2.1× 38 0.6× 15 0.3× 53 1.2× 35 575
Pascal Espié Switzerland 12 61 0.4× 106 1.6× 20 0.3× 13 0.3× 65 1.5× 21 625
S M Kalman United States 12 161 1.0× 155 2.3× 48 0.7× 29 0.7× 17 0.4× 17 532
Helmut Brasch Germany 13 47 0.3× 212 3.1× 53 0.8× 21 0.5× 63 1.5× 39 536

Countries citing papers authored by C. Aeschlimann

Since Specialization
Citations

This map shows the geographic impact of C. Aeschlimann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Aeschlimann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Aeschlimann more than expected).

Fields of papers citing papers by C. Aeschlimann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Aeschlimann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Aeschlimann. The network helps show where C. Aeschlimann may publish in the future.

Co-authorship network of co-authors of C. Aeschlimann

This figure shows the co-authorship network connecting the top 25 collaborators of C. Aeschlimann. A scholar is included among the top collaborators of C. Aeschlimann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Aeschlimann. C. Aeschlimann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Flisiak, Robert, Andrzej Horban, C. Aeschlimann, et al.. (2007). [787] THE REDUCTION OF BOTH CYCLOPHILIN B AND HCV-RNA BY THE CYCLOPHILIN INHIBITOR DEBIO-025 CONFIRMS THE IMPORTANCE OF CYCLOPHILIN B FOR HCV REPLICATION IN MAN. Journal of Hepatology. 46. S296–S296. 2 indexed citations
2.
3.
Peeters, Oswald M., N. M. Blaton, C. Aeschlimann, & J. Gál. (2004). (+)-1-{(2S)-2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl}-1H-imidazole mononitrate [(+)-(S)-miconazole nitrate]. Acta Crystallographica Section E Structure Reports Online. 60(3). o365–o366. 7 indexed citations
4.
5.
Aeschlimann, C., A Küpfer, H Schefer, & T. Cerny. (1998). Comparative pharmacokinetics of oral and intravenous ifosfamide/mesna/methylene blue therapy.. PubMed. 26(9). 883–90. 29 indexed citations
6.
Küpfer, A, C. Aeschlimann, & T. Cerny. (1996). Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy. European Journal of Clinical Pharmacology. 50(4). 249–252. 86 indexed citations
7.
Aeschlimann, C., T. Cerny, & A Küpfer. (1996). Inhibition of (mono)amine oxidase activity and prevention of ifosfamide encephalopathy by methylene blue.. Drug Metabolism and Disposition. 24(12). 1336–1339. 57 indexed citations
8.
Küpfer, A, et al.. (1994). Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue. The Lancet. 343(8900). 763–764. 132 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hisamitsu Nakahashi Breakdown of academic impact, for papers by Helene Markkanen Breakdown of academic impact, for papers by Merel van Nuland Breakdown of academic impact, for papers by Joseph J. Sikora Breakdown of academic impact, for papers by G. Gothóni Breakdown of academic impact, for papers by John Kemp Breakdown of academic impact, for papers by Tsutomu Arai Breakdown of academic impact, for papers by Pascal Espié Breakdown of academic impact, for papers by S M Kalman Breakdown of academic impact, for papers by Helmut Brasch
Rankless by CCL
2026